Market Overview

UPDATE: Goldman Sachs Upgrades Quest Diagnostics to Buy on Improved Fundamentals

Share:
Related DGX
7 Notable Stocks Trading Ex-Dividend Friday, September 30
Benzinga's Top Initiations

In a report published Thursday, Goldman Sachs analyst Isaac Ro upgraded the rating on Quest Diagnostics (NYSE: DGX) from Neutral to Buy, and raised the price target from $56.00 to $67.00.

In the report, Ro noted, “We upgrade shares of DGX to Buy from Neutral and raise our 6-month price target to $67 (from $56), which implies 17% upside. After underperforming the S&P, HC peers, and direct comp LH over the past 12 months, we believe DGX is now poised for a turnaround and we see multiple catalysts to drive share outperformance.”

Quest Diagnostics closed on Wednesday at $57.30.

Latest Ratings for DGX

DateFirmActionFromTo
Sep 2016CitigroupInitiates Coverage onNeutral
Aug 2016Mizuho SecuritiesDowngradesBuyNeutral
Jun 2016Jyske BankDowngradesSell

View More Analyst Ratings for DGX
View the Latest Analyst Ratings

Posted-In: Goldman SachsAnalyst Color Upgrades Analyst Ratings

 

Related Articles (DGX)

View Comments and Join the Discussion!